NUCB2 has been associated with poor prognosis in breast cancer, prostate cancer, endometrial carcinoma, and bladder cancer [50], while low expression levels of SLC7A2 in ovarian cancer were associated with a positive prognosis. Here, NUCB2 is linked to urinary bladder cancer.